Answers are grounded in this paper and cite their sources.
Background Large vWF (von Willebrand Factor) multimers are associated with ischemic stroke, and itsthrombogenicity is controlled by ADAMTS13 (a Disintegrin and Metalloprotease with repetitions in the ThromboSpond in motif). ADAMTS13 can cleave large vWF multimers into smaller, less procoagulant forms, preventing spontaneous platelet-thrombus formation. Extensive research has been conducted on the connection between ischemic stroke and ADAMTS13 activity as well as antigen levels, but got inconsistent conclusions. More recently, contradictory findings have been reported regarding the relationship between ADAMTS13 antigen levels or activity and recanalization therapy such as intravenous thrombolysis and mechanical thrombectomy. Methods A thorough literature search was conducted from July 2th, 2001 to April 7th, 2025, utilizing various online databases including PubMed, Cochrane Library, Web of Science, and EMBASE. This meta-analysis aimed to synthesize observational evidence on the association between ADAMTS13 antigen or activity and stroke, and to evaluate its potential influence on recanalization outcomes following intravenous thrombolysis or mechanical thrombectomy. The pooled relative risk (RR) of stroke and the standardized mean difference (SMD) of the ADAMTS13 for stroke versus control subjects, as well as their corresponding 95% confidence interval (CI) were calculated. Eighteen studies with a total of 8,993 participants were included into this meta-analysis. Results (1) ADAMTS13 activity was lower in patients with ischemic stroke when compared with controls, the SMD was −1.12 (95%CI: −1.20, −1.03, P < 0.001). Patients with ischemic stroke had decreased ADAMTS13 plasma antigen levels when compared to controls, the SMD was −1.32 (95%CI: −1.49, −1.15, P < 0.001). (2) The multivariable-adjusted relative risk (RR) indicated that lower ADAMTS13 levels were associated with an elevated risk of ischemic stroke, the RR was 1.75 (95%CI: 1.4, 2.19, P < 0.001). (3) Ischemic stroke patients who achieved unfavorable outcomes following recanalization therapy exhibited lower baseline ADAMTS13 antigen levels compared to those with favorable outcomes, the SMD was −0.26 (95%CI: −0.51, −0.01, P = 0.04). No significant difference in baseline ADAMTS13 activity was observed between patients with favorable and unfavorable outcomes following recanalization therapy, the SMD was −0.05 (95%CI: −0.36, 0.26, P = 0.75). (4) The multivariable-adjusted relative risk (RR) indicated that lower baseline ADAMTS13 levels were significantly associated with unfavorable early neurological outcome following recanalization therapy in ischemic stroke. However, no significant association was observed between baseline ADAMTS13 levels and 90-day functional outcomes in ischemic stroke patients without recanalization therapies, with a risk ratio (RR) of 0.92 (95%CI: 0.75, 1.12, P = 0.009). Conclusion ADAMTS13 activity and ADAMTS13 plasma antigen levels were lower in patients with ischemic stroke. Reduced ADAMTS13 levels were significantly correlated with an increased risk of ischemic stroke. Meanwhile, baseline ADAMTS13 antigen levels were lower in patients with unfavorable outcomes in ischemic stroke patients who undergoing recanalization therapy. Notably, lower ADAMTS13 levels are associated with unfavorable early neurological outcome after recanalization therapy in acute ischemic stroke rather than 90-day prognosis. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251229650 , Identifier: CRD420251229650.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: